These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2707049)

  • 1. Treatment of hyperlipidaemia with acipimox.
    Lintott CJ; Scott RS; Bremer JM
    Curr Med Res Opin; 1989; 11(6):374-9. PubMed ID: 2707049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acipimox in the treatment of patients with hyperlipidaemia: a double blind trial.
    Ball MJ; Vella M; Rechlass JP; Jones DB; Stirling C; Mann JI; Galton D
    Eur J Clin Pharmacol; 1986; 31(2):201-4. PubMed ID: 3803417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
    O'Kane MJ; Trinick TR; Tynan MB; Trimble ER; Nicholls DP
    Br J Clin Pharmacol; 1992 Apr; 33(4):451-3. PubMed ID: 1576071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability and efficacy of acipimox in type II hyperlipidaemia.
    Barlow CW; Soicher ER; Jankelow D; Myburgh DP
    S Afr Med J; 1990 May; 77(10):504-5. PubMed ID: 2343347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia.
    Ko GT; Mak TW; Yeung VT; Chan DC; Lam CW; Tsang LW; Chow CC; Cockram CS
    J Clin Pharmacol; 1998 Oct; 38(10):912-7. PubMed ID: 9807971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
    Series JJ; Gaw A; Kilday C; Bedford DK; Lorimer AR; Packard CJ; Shepherd J
    Br J Clin Pharmacol; 1990 Jul; 30(1):49-54. PubMed ID: 2390432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia.
    Dean JD; McCarthy S; Betteridge DJ; Whately-Smith C; Powell J; Owens DR
    Diabet Med; 1992; 9(7):611-5. PubMed ID: 1511566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolution of nicotinic acid-induced acanthosis nigricans by substitution of an analogue (acipimox) in a patient with type V hyperlipidaemia.
    Coates P; Shuttleworth D; Rees A
    Br J Dermatol; 1992 Apr; 126(4):412-4. PubMed ID: 1571266
    [No Abstract]   [Full Text] [Related]  

  • 9. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1998 May; 243(5):151-6. PubMed ID: 9651568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control.
    Shih KC; Kwok CF; Hwu CM; Hsiao LC; Li SH; Liu YF; Ho LT
    Diabetes Res Clin Pract; 1997 May; 36(2):113-9. PubMed ID: 9229195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
    Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
    Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.
    Koev D; Zlateva S; Susic M; Babic D; Profozic V; Skrabalo Z; Langrová H; Cvrkalová AL; Rajecová E; Klimes I
    Diabetes Care; 1993 Sep; 16(9):1285-90. PubMed ID: 8404433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.
    Otto C; Parhofer KG; Ritter MM; Richter WO; Schwandt P
    Br J Clin Pharmacol; 1998 Nov; 46(5):473-8. PubMed ID: 9833601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia--effects on serum lipids, lipoproteins, glucose tolerance and tolerability.
    Tornvall P; Walldius G
    J Intern Med; 1991 Nov; 230(5):415-21. PubMed ID: 1940776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term Acipimox decreases the ability of plasma from Type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux: a potentially adverse effect on reverse cholesterol transport.
    Dullaart RP; van Tol A
    Diabet Med; 2001 Jun; 18(6):509-13. PubMed ID: 11472472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.
    Simons LA; Hickie JB; Balasubramaniam S
    Atherosclerosis; 1985 Jan; 54(1):75-88. PubMed ID: 3888229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharma clinics. Drug of the month. Acipimox (Olbetam)].
    Scheen AJ
    Rev Med Liege; 1995 Nov; 50(11):489-90. PubMed ID: 8532997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.